NUS researchers harness AI to identify cancer cells by their acidity
Novel technique paves the way for faster, inexpensive and accurate cancer diagnosis
Credit: National University of Singapore
Singapore, 17 March 2021 – Healthy and cancer cells can look similar under a microscope. One way of differentiating them is by examining the level of acidity, or pH level, inside the cells.
Tapping on this distinguishing characteristic, a research team from the National University of Singapore (NUS) has developed a technique that uses artificial intelligence (AI) to determine whether a single cell is healthy or cancerous by analysing its pH. Each cancer test can be completed in under 35 minutes, and single cells can be classified with an accuracy rate of more than 95 per cent.
The research, led by Professor Lim Chwee Teck, Director of the Institute for Health Innovation & Technology (iHealthtech) at NUS, was first published in the journal APL Bioengineering on 16 March 2021.
“The ability to analyse single cells is one of the holy grails of health innovation for precision medicine or personalised therapy. Our proof-of-concept study demonstrates the potential of our technique to be used as a fast, inexpensive and accurate tool for cancer diagnosis,” said Prof Lim, who is also from the NUS Department of Biomedical Engineering.
Using AI for cancer detection
Current techniques for examining a single cell can induce toxic effects or even kill the cell. The approach developed by Prof Lim and his team, however, can distinguish between cells originating from normal and cancerous tissue, as well as among different types of cancer. Crucially, all of these can be achieved while keeping the cells alive.
The NUS team’s method relies on applying bromothymol blue – a pH-sensitive dye that changes colour according to the level of acidity of a solution – onto living cells. Due to its intracellular activity, each type of cell displays its own ‘fingerprint’ which consists of its own unique combination of red, green, and blue (RGB) components when illuminated. Cancer cells have an altered pH compared to healthy cells, so they react differently to the dye, and this changes their RGB fingerprint.
Using a standard microscope equipped with a digital colour camera, the RGB components emitted from the dye inside the cells are captured. By using an AI-based algorithm they developed, the NUS researchers were able to quantitatively map the unique acidic fingerprints so that the cell types examined can be easily and accurately identified. Thousands of cells originating from various cancerous tissues can be imaged simultaneously, and single-cell features can be extracted and analysed. Compared to current standard methods of cancer cell imaging which require several hours, the process developed by the NUS team can be completed in less than 35 minutes.
“Unlike other cell analysis techniques, our approach uses simple, inexpensive equipment, and does not require lengthy preparation and sophisticated devices. Using AI, we are able to screen cells faster and accurately. Furthermore, we can monitor and analyse living cells without causing any toxicity to the cells or the need to kill them. This would allow for further downstream analysis that may require live cells,” explained Prof Lim.
Opening the door for faster detection
As their technique is simple, low cost, fast and high-throughput, the research team is planning to develop a real-time version of this technique where cancer cells can be automatically recognised, and promptly separated for further downstream molecular analysis, such as genetic sequencing, to determine any possible drug treatable mutation.
“We are also exploring the possibility of performing the real-time analysis on circulating cancer cells suspended in blood,” shared Prof Lim. “One potential application for this would be in liquid biopsy where tumour cells that escaped from a primary tumour can be isolated in a minimally-invasive fashion from bodily fluids such as blood.”
In addition, the group is looking forward to advancing their concept to detect different stages of malignancies from the cells tested.
Related Journal Article